StemCell Therapy

Stress is a part of modern life. Thanks to a hectic lifestyle and a race to accomplish unrealistic deadlines, many people suffer from some degree of stress. But when it takes on a severe form, it can lead to many unwanted health conditions. This induces what is medically called stress induced arthritis. It is basically rheumatoid arthritis that is triggered by stress and anxiety. Also Read - Rheumatoid arthritis and workouts: These exercises will help alleviate the symptoms

Stress is the most common cause of inflammation, which leads to arthritis. Aches and pains are also common symptoms of stress. But when you suffer from chronic stress, this may take on a serious form. Stress contributes significantly to the development of autoimmune diseases, which makes the bodys immune system produce antibodies that attack the bodys healthy tissues instead of fighting infection. Arthritis, as we all know, is an autoimmune condition. In conditions like rheumatoid arthritis, the antibodies attach to connective tissue within the joints. This leads to pain, stiffness and swelling. It can go on to cause permanent joint damage if you dont take care immediately. Autoimmune diseases are mostly incurable. But you can manage the symptoms and delay progression. Also Read - Get relief from arthritis pain naturally: 5 home therapies you must try

If you suffer from this form of arthritis, you will experience symptoms that are common to other types of arthritis. Stiffness in your joints, painful and swollen joints and morning stiffness are common. You may also get tired easily and have fever from time to time. Other symptoms of this condition are unexplained loss of appetite, weight loss, numbness and tingling of limbs and insomnia. Anxiety attacks and difficulty in breathing are also common. Also Read - Best exercises for juvenile arthritis

Besides consulting your doctor, there are a few other things that you can do to deal with the symptoms of this condition. Let us see what they are.

If you are in pain, it is natural that you may not want to exercise daily. But if you can force yourself to do so, you will be surprised to see the difference that it makes. Take up some low impact exercises like walking, swimming, yoga or aerobics. This will give you relief from your arthritis pain and improve flexibility in your joints. You can also take up a bit of weight training. But if you find that your pain increases because of your workouts, stop immediately and consult a doctor.

Try to be relaxed and calm. This will improve your condition significantly. You can try yoga and some meditation techniques for this, listen to music, read a good book and do some breathing exercises. If you can manage your stress, your condition will automatically improve.

This is important because it will boost your overall health and help you deal with the challenges thrown up by arthritis. Include a lot of fresh fruits and vegetables in your diet. Make sure your meals are nutritious and balanced. Avoid processed and fried foods and try to go easy on sugar. All this will make a significant difference to your health.

Published : May 29, 2020 10:14 am | Updated:May 29, 2020 11:52 am

Read the rest here:
Symptoms of stress induced arthritis: Know how to deal with it naturally - TheHealthSite

by Elizabeth Hofheinz, M.P.H., M.Ed.

A team of researchers from Hospital for Special Surgery (HSS) studying 2,600 patients has found that the percentage of patients with hip osteoarthritis (OA) who had a hip replacement within two years of hip arthroscopy was a whopping 68%. In addition, having undergone prior hip arthroscopy was associated with significantly worse outcomes after hip replacement.

Their study, Hip arthroscopy for hip osteoarthritis is associated with increased risk for revision after total hip arthroplasty, appeared in the March 3, 2020 online edition of Hip International.

Alexander McLawhorn, M.D., M.B.A., a hip and knee surgeon at HSS, told OSN, We had observed suboptimal outcomes and more complications after total knee replacement in patients with prior knee arthroscopy compared to patients who had never had a knee arthroscopy. Also, we had observed that patient reported outcomes patients subjective assessment of their outcomes after total hip replacement were lower in patients who had prior hip arthroscopy versus those who did not.

The study, the first to quantify the clinical outcomes and risks of complications of hip arthroscopy before total hip replacement in OA patients, is available online as part of theAAOS 2020 Virtual Education Experience and is currently publishedonlineonHIP International.

Using Medicare data from a large national insurance database (PearlDiver Patient Records Database), the team identified more than 5,200 patients with hip arthritis who had undergone a total hip replacement procedure between 2005 and 2016. Patients were categorized as to whether they had received hip arthroscopy before hip replacement; there were 2,600 patients in each group.

Dr. McLawhorn commented to OSN, First, there was a very high rate of conversion to total hip replacement within two years of hip arthroscopy, when arthroscopy was performed in the setting of hip arthritis. Second, there was a significantly higher odds of serious complications, including reoperation, infection, implant loosening and dislocation, after hip replacement in patients with a history of prior hip arthroscopy.

Indeed, 1,790 (68%) of patients who had received hip arthroscopy for OA had undergone a total hip replacement procedure within two years. According to the study, Patients who had a prior hip arthroscopy had 3.7 times greater risk of needing revision hip replacement surgery, 2.8 times greater risk of implant loosening and 1.9 times higher risk of joint infection after hip replacement, compared to patients who had not had hip arthroscopy prior to their hip replacement.

Within two years of total hip replacement, 3.4% of patients in the arthroscopy group required revision surgery compared to 2.1% in the non-arthroscopy group. In the same period, rates of complications were higher for the arthroscopy group compared to the non-arthroscopy group as follows: dislocation 3.2% versus 2.3%; joint infections 2.9% versus 1.6%; and joint loosening 2.3% versus 1.0%, respectively.

Dr. McLawhorn told OSN, In the majority of patients with hip arthritis, hip arthroscopy is probably a low value procedure to be avoided or approached with extreme caution. Surgeons often focus on potential benefits of interventions without appropriate acknowledgement of potential risks. In this case, if hip arthroscopy is offered to patients with underlying hip arthritis, the real risk of conversion to total hip replacement should be discussed along with the potential negative effects of arthroscopy on the subsequent replacement.

I think it should be noted that there may be a subset of patients with hip arthritis who benefit from hip arthroscopy (with or without concomitant interventions), as one third of patients did not undergo immediate conversion to total hip replacement. This population deserves closer study in order to refine the indications, if any, for hip arthroscopy in the arthritic hip.

Originally posted here:
Study: Hip Arthroscopy for OA=High Conversion to THR, Worse Outcomes - OrthoSpineNews

A new report by XploreMR takes a deep dive into the Rheumatoid Arthritis Treatment after exhaustively researching, analyzing, and assessing the markets global and regional trends to encourage market players to improve their business tactics and succeed in the long-run. The extensively detailed study is simplified on the basis of the markets end-use applications, regional adoption, products, and various other segments, to provide insightful learning to the market players. The researchers present a highly detailed study written in simple English and backed by simple images to represent statistics which is an effective tool to understand the market dynamics, and gain a competitive edge in the Rheumatoid Arthritis Treatment Market. Dwelling deep into compelling details, the report also discusses the developments in the competitive landscape and various growth strategies being implemented by the players in the Rheumatoid Arthritis Treatment Market.

Numerous players in the Rheumatoid Arthritis Treatment Market have been studied based on service and application portfolios, market share, and growth potential, among other details, which are sure to empower individual players in adapting strategies to gain dominance. The report also indulges in forecasting trends, supply-side demands, strategies of players, and how these will change during the forecast period, thereby preparing market players to act accordingly. The way leading market players are implementing strategies and reshaping them based on emerging trends has been given high importance. Understanding the same will bolster market players in making appropriate business decisions, and guide them on a profitable path through the forecast period. Besides, discerning the possible changes in the market will ensure that the market players gain a competitive advantage and continue their growth trajectory.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/2263

The report covers exhaustive analysis on:

Regional analysis includes

The researchers have highly emphasized on Compound Annual Growth Rate (CAGR) to represent the growth of the market and individual segments in terms of both volume and value. The CAGR paints a clear picture of how segments are expected to fare through the forecast period, and their standpoint by the end of it. The CAGR gives a crystal clear idea of how much a segment is anticipated to grow, thereby allowing market players to focus on the most lucrative areas of the Rheumatoid Arthritis Treatment Market. Ranging from a particular product to a country, the CAGR leaves no stone unturned in presenting segmental highlights concerning each region, thereby empowering regional players to capitalize on the segments that are expected to flourish in their region. Moreover, the report sheds light on region-specific trends, enabling regional players to leverage emerging trends and generate revenue through the forecast period 2019 2029.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/2263

Important Questions Answered

The researchers have analyzed macro-economic factors such as political, economic, social, technological, environmental, and legal developments, to derive the drivers and restraints of the Rheumatoid Arthritis Treatment Market. Excessive study of the political and economic landscape of all major regions has been done to present the factors that will impel the market revenue. On the other hand, consumer behavior across the globe has been scrutinized to understand the possible growth restraints, in addition to other macro factors. Understanding the restraining factors empowers market players to mitigate the possible risks that they may have to deal with during the forecast period 2019 2029.

The report provides a comprehensive study of the Rheumatoid Arthritis Treatment Market, with details ranging from assessment of companies to trends to geography-specific drivers and restraints. Additionally, the study presents segmental highlights and competitive landscape concerning each geography. Authored by researchers after extensive analysis, the report is suffused with key insights into the global Rheumatoid Arthritis Treatment Market, and will ensure that the readers gain a comprehensive understanding of the direction the Rheumatoid Arthritis Treatment Market is headed in.

Get Full Report Access athttps://www.xploremr.com/cart/2263/SL

Highlights of TOC:

Overview:Presents a broad overview of the Rheumatoid Arthritis Treatment Market, acting as a snapshot of the elaborate study that follows.

Market Dynamics:A straight-forward discussion about key drivers, restraints, challenges, trends, and opportunities of the Rheumatoid Arthritis Treatment Market.

Product Segments:Explores the market growth of the wide variety of products offered by organizations, and how they fare with end-users.

Application Segments:This section studies the key end-use applications that contribute to the market growth and the emerging opportunities to the Rheumatoid Arthritis Treatment Market.

Geographical Segments:Each regional market with a region-specific study of each segment- is carefully assessed for understanding its current and future growth scenarios.

Company Profiles:Leading and emerging players of the Rheumatoid Arthritis Treatment Market are thoroughly profiled in the report based on their market share, market served, products, applications, regional growth, and other factors.

Why Do Companies Trust XMR?

About Us

XploreMR, a leading market research firm, headquartered in San Jose, USA, XploreMR has, in a short span of time, served the market research needs of some of the biggest Fortune 500 companies. XploreMR also has highly personalized market research offerings for SMEs, and we pride ourselves on being uniquely positioned to have worked with colossal multinational firms and small, boutique firms. Our experience of working with such a diverse set from all over the world has given us invaluable perspectives on objectives, outlooks, goals, and eventually, the collective, symbiotic growth that stakeholders across the value chain aspire for. We keep these perspectives and aspirations in mind every time we work on a project, and this motivates us to exceed client expectations on a consistent basis

Contact us:

XploreMR

111 North Market Street, Suite 300,

San Jose, CA 95113, United States

Ph.No: +16692840108

E-mail id- sales@xploremr.com

Web:https://xploremr.com/

The rest is here:
Rheumatoid Arthritis Treatment Market: Expansion Strategies Set to Generate Substantial Revenue in the... - Azizsalon News

For patients with rheumatoid arthritis (RA), cost can play a role in patient adherence to medication, but the presence of comorbidities does not impact cost of care for patients, according to 2 abstracts presented at the Virtual 2020 International Society for Pharmacoeconomics and Outcomes Research meeting.

In one study,1 researchers used a pooled cross-sectional analysis of 2009-2013 Medicare Current Beneficiary Surveydata to assess the association between drug coverage type and out-of-pocket (OOP) medication cost with cost-related nonadherence (CRN) for patients with RA in the Medicare population.

Drug coverage type included in the analysis could be no coverage, standalone Medicare prescription drug plan, Medicare Advantage Prescription Drug (MAPD) plan, prescription drug plan plus Medicaid, MAPD plus Medicaid, TRICARE, and private plans. There were 4 questions that identified CRN with either a yes or no:

Patients with MADP plus Medicaid (HR, 0.18; 95% CI, 0.05-0.71;P = .01), TRICARE (HR, 0.12; 95% CI, 0.02-0.76;P = .02), or private plans (HR, 0.43; 95% CI, 0.26-0.73;P < .01) were less likely to report CRN than those without drug coverage, the authors wrote.

In the second study,2 researchers evaluated 2140 patients with RA to understand their RA-related outpatient treatment costs. All the patients included were being treated with biologic disease-modifying antirheumatic drugsbetween April 2016 and March 2018. They were followed for 12 months.

The majority (82%) had at least 1 comorbidity. Patients with comorbidities were more likely to be older, white, female, and Medicare insured compared with patients without comorbidities. Before accounting for demographics, patients with comorbidities had higher total RA costs ($56,405 vs $49,298), but after accounting for differences in demographics using generalized linear models, the difference in costs shrunk ($52,209 vs $48,484), and after using propensity score matching (350 patients per group matched without replacement by age, race, payer, and gender), the difference in costs disappeared ($47,697 vs $47,612).

References

1. Zheng D, Thomas J. Prescription drug coverage type, out-of-pocket spending, and cost-related nonadherence among Medicare beneficiaries with rheumatoid arthritis. Presented at: ISPOR 2020; May 18-20, 2020; Abstract PMS81.https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/102115

2. Edgerton C, Radtchenko J, Holers VM. Outpatient costs in rheumatoid arthritis (RA) patients with vs without comorbidities. Presented at: ISPOR 2020; May 18-20, 2020; Abstract PMS4.https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/99754

See the original post:
How Comorbidities Affect Costs and Costs Impact Nonadherence in RA - AJMC.com Managed Markets Network

Roche and Gilead Sciences have launched a Phase III clinical trial in severe COVID-19 pneumonia, testing Roches Actemra/RoActemra with Gileads remdesivir. To date, remdesivir is the only drug shown to be effective against COVID-19 and is approved by the U.S. Food and Drug Administration (FDA) under emergency use authorization.

Actemra/RoActemra is an anti-IL-6 receptor biologic in both intravenous and subcutaneous formulations for adults with moderate-to-severe active rheumatoid arthritis (RA). It is also used to treat polyarticular juvenile idiopathic arthritis, giant cell arteritis and for chimeric antigen receptor CAR-T-cell-induced severe or life-threatening cytokine release syndrome (CRS).

ad

In other words, Actemra/RoActemra is used to treat inflammatory diseases and to control the cytokine storms associated with certain immuno-oncology treatments. Gileads remdesivir is an antiviral drug. COVID-19 is marked by several unusual symptoms, including blood clotting, cytokine storms and severe pneumonia.

As more information about COVID-19 pneumonia becomes available in these unprecedented times, it is more important than ever to work together to fight this disease, said Levi Garraway, Roches chief medical officer and head of Global Product Development. Based on our current understanding, we believe that combining an antiviral with an immune modulator could potentially be an effective approach to treating patients with severe disease. Were pleased to partner with Gilead to determine whether combining these medicines could potentially help more patients during this pandemic.

The REMDACTA Phase III trial is expected to begin enrolling in June and involve 450 patients worldwide.

Roche is also almost done with enrollment of another Phase III trial, COVACTA, studying intravenous Actemra/RoActemra alone with standard of care (SOC) compared to placebo plus SOC in hospitalized adults with severe COVID-19 pneumonia. The original design called for 330 patients but was expanded to allow for more robust data. The first patient was randomized on April 3, with about 450 patients enrolled. The company expects to share data from the COVACTA trial sometime this summer. The protocol for COVACTA allows patients who were treated with antiviral drugs, including experimental antivirals, so data from that subgroup can be used to supplement the COVACT study.

COVACTA is being run in partnership with the FDA and the Biomedical Advanced Research and Development Authority (BARDA). Roche is also taking part in the Accelerated COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership led by the National Institutes of Health (NIH) and the Foundation of the NIH.

As mentioned above, in a study conducted by the U.S. National Institute of Allergy & Infectious Diseases (NIAID) of remdesivir in 1,063 COVID-19 patients, the drug showed on April 30 that patients recovered from the disease faster than patients who received placebo. This prompted the emergency use authorization by the FDA within days. What it showed was patients had a 31% faster time to recovery than the placebo group, from a median 15 days to a median 11 days.

The detailed data was published yesterday in The New England Journal of Medicine. Additional data suggested remdesivir was a little bit better in decreasing deaths than were originally reported, although the difference wasnt statistically significant. Previously, death rates were 8% with the drug compared to 11.6% in the placebo groups. With additional two-week data, the rate for remdesivir was 7.1% compared to 11.9% for the placebo.

In a note to clients written on Saturday, May 23, Geoffrey Porges, analyst with SVB Leerink, said the numeric mortality improvement, if further validated, can change sentiment about COVID-19. In addition, the improvement can take some of the stress off hospital systems.

The drug didnt seem to provide much help to COVID-19 patients with mild or moderate disease and patients on invasive ventilation or extracorporeal membrane oxygenation were almost identical in both arms of the trial. The likelihood in improvement in clinical status was 50% higher in patients receiving remdesivir than in the placebo cohort.

Porges wrote, It is likely that the treatment benefit from remdesivir will increase in the real world once the lessons of this trial and other studies are incorporated into routine treatment practices.

Umer Raffat, an analyst with Evercore noted of the published study data, The single most important data disclosure that I was awaiting was this: How does mortality look different in patients that take remdesivir early? These early trials on COVID are all about identifying not only whether a drug works, but also when to initiate the drug.

Read more here:
Roche and Gilead Launch COVID-19 Trial to Test One-Two Punch of Actemra and Remdesivir - BioSpace

The Systemic Idiopathic Juvenile Arthritis Treatment market research encompasses an exhaustive analysis of the market outlook, framework, and socio-economic impacts. The report covers the accurate investigation of the market size, share, product footprint, revenue, and progress rate. Driven by primary and secondary researches, the Systemic Idiopathic Juvenile Arthritis Treatment market study offers reliable and authentic projections regarding the technical jargon.All the players running in the global Systemic Idiopathic Juvenile Arthritis Treatment market are elaborated thoroughly in the Systemic Idiopathic Juvenile Arthritis Treatment market report on the basis of proprietary technologies, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines R&D developments, legal policies, and strategies defining the competitiveness of the Systemic Idiopathic Juvenile Arthritis Treatment market players.The report on the Systemic Idiopathic Juvenile Arthritis Treatment market provides a birds eye view of the current proceeding within the Systemic Idiopathic Juvenile Arthritis Treatment market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Systemic Idiopathic Juvenile Arthritis Treatment market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2534385&source=atm

The following manufacturers are covered:Alteogen Inc.Bristol-Myers Squibb CompanyEpirus Biopharmaceuticals, Inc.Johnson & JohnsonMomenta Pharmaceuticals, Inc.Mycenax Biotech Inc.Novartis AGOncobiologics, Inc.

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeAdalimumab BiosimilarCanakinumabGolimumabTocilizumab BiosimilarOthers

Segment by ApplicationClinicHospitalOthers

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2534385&source=atm

Objectives of the Systemic Idiopathic Juvenile Arthritis Treatment Market Study:To define, describe, and analyze the global Systemic Idiopathic Juvenile Arthritis Treatment market based on oil type, product type, ship type, and regionTo forecast and analyze the Systemic Idiopathic Juvenile Arthritis Treatment market size (in terms of value and volume) and submarkets in 5 regions, namely, APAC, Europe, North America, Central & South America, and the Middle East & AfricaTo forecast and analyze the Systemic Idiopathic Juvenile Arthritis Treatment market at country-level for each regionTo strategically analyze each submarket with respect to individual growth trends and their contribution to the global Systemic Idiopathic Juvenile Arthritis Treatment marketTo analyze opportunities in the market for stakeholders by identifying high growth segments of the global Systemic Idiopathic Juvenile Arthritis Treatment marketTo identify trends and factors driving or inhibiting the growth of the market and submarketsTo analyze competitive developments, such as expansions and new product launches, in the global Systemic Idiopathic Juvenile Arthritis Treatment marketTo strategically profile key market players and comprehensively analyze their growth strategiesThe Systemic Idiopathic Juvenile Arthritis Treatment market research focuses on the market structure and various factors (positive and negative) affecting the growth of the market. The study encloses a precise evaluation of the Systemic Idiopathic Juvenile Arthritis Treatment market, including growth rate, current scenario, and volume inflation prospects, on the basis of DROT and Porters Five Forces analyses. In addition, the Systemic Idiopathic Juvenile Arthritis Treatment market study provides reliable and authentic projections regarding the technical jargon.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2534385&licType=S&source=atm

After reading the Systemic Idiopathic Juvenile Arthritis Treatment market report, readers can:Identify the factors affecting the Systemic Idiopathic Juvenile Arthritis Treatment market growth drivers, restraints, opportunities and trends.Examine the Y-o-Y growth of the global Systemic Idiopathic Juvenile Arthritis Treatment market.Analyze trends impacting the demand prospect for the Systemic Idiopathic Juvenile Arthritis Treatment in various regions.Recognize different tactics leveraged by players of the global Systemic Idiopathic Juvenile Arthritis Treatment market.Identify the Systemic Idiopathic Juvenile Arthritis Treatment market impact on various industries.

Excerpt from:
Assessing the Fallout From the Coronavirus Pandemic Systemic Idiopathic Juvenile Arthritis Treatment Market To Grow Significantly From 2020 To 2026,...

In the United States, 23 percent of adults suffer from arthritis. Around the world, 350 million people have this condition. While most people who have arthritis are age 65 or older, there are still many young and middle-aged adults who also have this condition.

Unfortunately, there is no known cure for arthritis. The best thing that scientists can currently do for the condition is alleviate the symptoms and slow down the progression of the disease. By reducing the bodys inflammatory response, doctors can help you live in less pain for longer. While every drug carries some risks and side effects, cannabidiol (CBD) is showing promise as a way to treat the pain of arthritis and reduce the progression of the disease.

How Does CBD Help?

Thanks to the passage of the 2018 Farm Bill, farmers can now grow and process hemp in the United States. Because of this, CBD is now widely available online for people across the country. In addition to helping with conditions like insomnia and anxiety, research also shows that CBD can help alleviate pain as well.

CBD is a chemical compound that is naturally found within cannabis plants. While this compound will not make you high, it does have other useful benefits. Since cannabis was completely illegal until very recently, scientists are still working to understand the effects of using cannabis. CBD is only one out of dozens of different cannabinoids in cannabis, so other cannabinoids may have additional effects as well.

In the United States, people can readily buy CBD balm, tinctures, vaporizers and gummies. One study by Harris Poll found that 85 percent of Americans have already heard about CBD. Out of these adults, more than 20 percent have actually tried it.

Once CBD is extracted from cannabis, it can be used to treat ailments ranging from anxiety to chronic stress. CBD works by targeting receptors in the endogenous cannabinoid system. The cannabinoid system consists of neurotransmitters that naturally bind to cannabinoid receptors. These cannabinoid receptor proteins are naturally made in the human body. CBD targets the same receptors in order to alleviate pain, anxiety and stress.

Currently, about 55 percent of users state that they take CBD in order to relax. An estimated half of people use CBD for anxiety and stress. The next most common reason why people used CBD was for pain. In addition, some people use CBD for menstrual symptoms, migraines, nausea and sexual enhancement.

What Does the Research Say?

Because CBD was illegal like the rest of the cannabis plant, researchers are still trying to gain a better understanding of how effective this drug is for various conditions. In addition, researchers still need to figure out effective dosages. In rats, moderate doses of CBD have been shown to produce an anti-anxiety effect.

Another rat study shows that oral and topical solutions of CBD can help to alleviate pain. This particular study involved scientists exposing the rats sciatic nerves using an incision. Then, they constricted the nerves. Another part of the study involved injecting bacteria into the rats paws to cause inflammation. Afterward, the scientists gave the rats CBD or a placebo for a week. They applied pressure or heat to the rats legs to see how their reaction changed in comparison to their pre-study reactions. The rats that received CBD had less pain than the control group.

In a 2010 study of human patients, 177 people experiencing cancer-related pain were given extracts of tetrahydrocannabinol (THC) and CBD. The patients who received extracts with THC and CBD were twice as likely to experience pain relief as the patients who received just THC. This seems to indicate that CBD alone or the combination of the two is the component that leads to pain relief.

Looking for reliable CBD products backed by lab-test results? Check out RealTestedCBD.

CBD and Arthritis Pain

An estimated 54 million Americans suffer from arthritis. Out of this number, 24 million Americans have to limit their daily activities because of arthritis. While people may say they just have arthritis, arthritis is actually a term that covers more than 100 different conditions. All of these conditions involve some level of swelling, pain and stiffness. With certain kinds of arthritis, the organs can also be affected.

The most common type of arthritis is osteoarthritis. This is the form that causes cartilage to deteriorate. Since this cartilage helps to protect your bones from friction, it can lead to pain and joint damage. People who experience this condition can develop inflammation as well. Because it takes time for cartilage to deteriorate, this condition typically affects the elderly more than it affects young adults.

Inflammatory arthritis like psoriatic and rheumatoid arthritis are connected to autoimmune conditions. These kinds of conditions develop because the immune system thinks that it is under attack from invaders. Instead of attacking invading viruses, the body attacks organs or bones. This leads to severe pain and inflammation.

Once someone experiences joint deterioration, the symptoms tend to get worse over time. Other than treating joint and nerve pain, many patients also need help with inflammation. By using CBD, you might be able to limit your joint pain, inflammation and mobility issues. Arthritis symptoms like stiffness, decreased joint movement and pain tend to respond well to CBD.

How the Endocannabinoid System Works

The endocannabinoid system is a fairly recent discovery. It was discovered after researchers started learning about the way cannabis affects the body, which is how this system got its name. People have used cannabis for therapeutic purposes for centuries. In 1964, researchers finally managed to isolate THC. Amazingly, this was the first time scientists learned how cannabis made people high.

Out of all of the cannabinoids, THC is the most abundant in the plant. THC affects neuronal signaling in the body. During the 1990s, researchers found different cannabinoid receptors in the body. Researchers discovered that THC binds with CB1 receptors in the central nervous system. Outside of the central nervous system, THC binds with CB2 receptors. CBD is also thought to work closely with CB2 receptors, which are known to regulate the immune system.

The human body does not have cannabinoid systems and receptors by accident. These receptors were designed to work with natural cannabinoids that your body produces. There are actually two other types of endocannabinoid receptors, but scientists are still uncertain about what these receptors do.

Your cannabinoid system is responsible for processes involving learning, executive function, memory, emotions, sensory reception, motor function and decision making. Your cannabinoid receptors are located in the central nervous system and peripheral nerves. By making changes to the endocannabinoid system by taking CBD, you may be able to reduce your perceived pain and change any processes that are affected by the cannabinoid system.

The Benefits of CBD for Arthritis

Recent studies show that 42 percent of Baby Boomers already use CBD to help with their joint point. In animal research, CBD has been shown to have antioxidant, anti-inflammatory and pain-relieving properties. By taking CBD, you may be able to reduce the signs and symptoms of arthritis.

Pain Suppression

One of the major reasons why people use CBD for arthritis is to reduce pain. Recent studies show that 62.2 percent of marijuana users took marijuana for pain relief. Almost all seniors experience some kind of pain later in life, and CBD can help reduce this pain. Cannabis and CBD are especially useful for joint pain from conditions like arthritis.

Nerve Protectant

Interestingly, CBD can also protect your nerves. It helps to reduce joint neuropathy. This is one of the reasons why it is useful for conditions like arthritis, multiple sclerosis and cancer.

Joint Support

Another one of the ways CBD can help is by supporting the joints. Taking CBD can reduce the inflammation around your joints. Reduced inflammation can also improve the symptoms of other diseases as well.

Insomnia Reduction

When you are in a lot of pain, it can feel impossible to sleep at night. In one study of Sativex and rheumatoid arthritis, many participants were able to sleep better when they used the drug. Cannabinoid products can help reduce physical discomfort and inflammation, which can naturally improve the quality of your sleep.

How Can You Use CBD?

You no longer have to roll a joint to use cannabis. Instead, there is a wide variety of different methods available for taking CBD. From edibles to topicals, you can choose the option that works best for you.

Until recently, the legality of CBD was in question. Some states legalized medical marijuana and recreational marijuana, but marijuana was still illegal on a federal level. Since CBD is made from the cannabis plant, this essentially meant that CBD was illegal.

More recently, the 2018 Farm Bill finally became law. This bill essentially legalized hemp under federal law with a few important caveats. While growers could produce hemp and CBD, they were not allowed to produce THC. Farmers can legally grow hemp, but the hemp is not allowed to have any THC in it.

Is CBD Safe?

One of the biggest problems with CBD is knowing how much to take and which drugs to avoid. Because CBD has not gone through major clinical trials yet, there are still many unknowns about things like the dosage and other factors. If a medication is strong enough to cause a cure, it is safe to assume that it is also strong enough to cause side effects and drug interactions. Current research and anecdotal reports generally indicate very few side effects associated with CBD, but there are some potential risks to keep in mind.

Because of the potential side effects, it is important to talk to your doctor before taking CBD. This is especially important if you have other medical conditions or take any medications. CBD can change how prescription medications are processed in the liver. This means it can potentially cause drug interactions with medications like Zofran, Clozaril, Endometrin, Luminal, Valium, Prilosec, Motrin, Celebrex, Paxil and Allegra.

In general, most experts agree that CBD is safe to take. It carries very low risks. Currently, there has never been a reported case of a CBD overdose. CBD can potentially cause drowsiness for some users, so you should remember this if you plan on operating heavy machinery or driving.

How Can You Use CBD for Arthritis?

When you first start using CBD, it is a good idea to start with a low dosage. By doing this, you can give your body time to adjust to the medication. If you do not see results, you can always increase your dose later on. Most people take CBD twice a day. In the beginning, people often start with a dose between 5 and 10 milligrams. If this does not alleviate your symptoms, you can gradually increase your dosage incrementally until you reach up to 100 milligrams a day.

While scientists still do not know how all of the cannabinoids work, it seems like some cannabinoids work better when they are taken together. For example, taking THC and CBD at the same time may increase the effectiveness of your dose. With a full-spectrum oil or isolate, you can get a range of cannabinoids instead of just CBD.

For arthritis pain, some people start by just using the product at night so that they can sleep better. You can also start by using a topical product or vaping so that you get immediate effects. Then, you can use edibles. Candies and edible products take longer to take effect, but the effects last longer. Vaping the extract allows CBD to get into your bloodstream quickly, which is useful for acute pain relief.

If you use CBD orally, remember that your body may be unable to absorb the CBD for around an hour. Once the oral CBD is absorbed, it can last for a long time. If you have localized pain, you may want to use a topical remedy like a salve, lotion or balm instead. When you apply a CBD gel on the affected area, you can instantly get relief for acute pain, swelling and inflammation.

Follow this link:
The Ultimate Guide to CBD and Seniors With Arthritis - Riverfront Times

Data from several studies have indicated the need for treatment of rheumatoid arthritis (RA) as early as possible, according to a report published in The Lancet Rheumatology.1

Early arthritis treatment has been used to improve long-term outcomes and minimize structural damage resulting from both local and systemic inflammation. In addition, many researchers believe that treatment will be most effective with early intervention (eg, within 6 weeks after symptom onset).2 A recent study that included patients at risk for RA also found that multiple pathologic processes can be observed before symptoms develop, promoting the need for early intervention.3

Furthermore, data from a meta-analysis4 found that patients who consulted with a rheumatologist 6 weeks vs 7 to 12 weeks and >12 weeks after symptom onset were 1.7 times more likely to achieve disease-modifying antirheumatic drug (DMARD)-free remission. This trend of being less likely to achieve DMARD-free remission was observed to continue with initial visits after 12 weeks of symptom onset. Since DMARD-free remission is considered a highly desirable outcome for patients with RA, the evidence supports more aggressive treatment during early stages of the disease. Authors of this report indicated that further assessing remission data (eg, at 5 years of DMARD-free remission) could be useful in determining rates of sustained remission.

Despite these findings, there was little difference in structural damage among patients with different time to encounters, which may be at odds with the long-standing hypothesis that earlier intervention leads to minimized structural damage; however, this lack of correlation could suggest that small degrees of damage are less important for outcomes in patients who receive early treatment.

Overall, the authors of this report concluded that findings from various studies confirm the need for rapid referral and treatment of RA after symptom onset.

References

1. Emery P, Dequenne L. Its never too soon to treat rheumatoid arthritis: finally, some supportive evidence [published online April 28, 2020]. Lancet Rheumatol. doi:10.1016/S2665-9913(20)30103-X

2. Combe B, Landewe R, Daien CI, Hua C, Aletaha D et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017;76:948-959.

3. Nam JL, Hensor EMA, Hunt L, Conaghan PG, Wakefield RJ, Emery P. Ultrasound findings predict progression to inflammatory arthritis in anti-CCP antibody-positive patients without clinical synovitis. Ann Rheum Dis. 2016;75:2060-2067.

4. Niemantsverdriet E, Dougados M, Combe B, van der Helm-van Mil AHM. Referring early arthritis patients within 6 weeks versus 12 weeks after symptom onset: an observational cohort study [published online April 28, 2020]. Lancet Rheumatol. doi:10.1016/S2665-9913(20)30061-8

Originally posted here:
Evidence Points to the Effectiveness of Early Treatment in Rheumatoid Arthritis - Rheumatology Advisor

Objective:We aimed to evaluate the associations between response to algorithm-directed treat-to-target conventional synthetic disease-modifying antirheumatic drug therapy and potentially modifiable lifestyle factors, including dietary fish oil supplementation, body mass index (BMI), and smoking history in a rheumatoid arthritis (RA) inception cohort.

Methods:Patients with RA with a duration of less than 12 months were reviewed every 3 to 6 weeks to adjust therapy according to disease response. All patients received advice to take fish oil supplements, and omega-3 status was measured as plasma levels of eicosapentaenoic acid (EPA). Lifestyle factors and other variables potentially prognostic for 28-joint Disease Activity Score (DAS28) remission and DAS28 low disease activity (LDA) at the 12-month visit were included in multivariable logistic regression models.

Results:Of 300 participants, 57.7% reached DAS28 LDA, and 43.7% were in DAS28 remission at 1 year. Increase in plasma EPA was associated with an increase in the odds of being in LDA (adjusted odds ratio [OR] = 1.27; P < 0.0001) and remission (adjusted OR = 1.21; P < 0.001). There was some evidence that the effect of BMI on LDA might be modified by smoking history. An increase in BMI was associated with a decrease in the odds of being in LDA in current and former smokers but had no impact on LDA in patients who had never smoked. There were no meaningful associations between BMI or smoking history and remission.

Conclusion:Omega-3 status, BMI, and smoking history are potential predictors of outcome in early RA. The possibility of an effect modification by smoking on the predictive value of BMI merits further investigation.

See original here:
Modifiable Lifestyle Factors Associated With Response to Treatment in Early Rheumatoid Arthritis - DocWire News

The report on the Rheumatoid Arthritis (RA) Drugs market provides a birds eye view of the current proceeding within the Rheumatoid Arthritis (RA) Drugs market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Rheumatoid Arthritis (RA) Drugs market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Rheumatoid Arthritis (RA) Drugs market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Rheumatoid Arthritis (RA) Drugs market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Rheumatoid Arthritis (RA) Drugs market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2675994&source=atm

The major players profiled in this Rheumatoid Arthritis (RA) Drugs market report include:

Key market playersMajor competitors identified in this market include AbbVie, Roche, Johnson & Johnson, Amgen, Inc., Pfizer, Merck, Bristol-Myers Squibb, UCB, GlaxoSmithKline, Sanofi, Abbott Laboratories, Teva Pharmaceutical, etc.

Based on the Region:Asia-Pacific (China, Japan, South Korea, India and ASEAN)North America (US and Canada)Europe (Germany, France, UK and Italy)Rest of World (Latin America, Middle East & Africa)

Based on the Type:OralInjectionExternal

Based on the Application:Medical CarePersonal Care

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2675994&licType=S&source=atm

Key Market Related Questions Addressed in the Report:

Important Information that can be extracted from the Report:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2675994&source=atm

Read the original:
COVID-19: Potential impact on Ready To Use Rheumatoid Arthritis (RA) Drugs Market Global Industry Analysis and Forecast Till 2021 - Jewish Life News

Kenneth Research recently added a new market research report on Global Reactive Arthritis Treatment Market which discusses the scope of the market during the next few years. The report consists of the market size, market value, the annual growth rate, Y-o-Y growth (%) for the forecast period, i.e., 2020-2026. A complete and thorough overview of the market is provided in the report which discusses the various aspects of the market such as the geographical presence, key players, market segmentation, growth drivers, and challenges prevalent in the market in depth.

The Final Report will cover the impact analysis of COVID-19 on this industry (Global and Regional Market).

Request for a Sample Copy (including TOC, Tables, and Figures) of Research Report:https://www.kennethresearch.com/sample-request-10082863

The global Reactive Arthritis Treatment Market has grown significantly over the past few years and is anticipated to expand at a rapid pace till 2026. This market study provides an in-depth assessment on market size and year on year growth of global Reactive Arthritis Treatment Market in terms of revenue, various levels of in-depth market segmentation, market dynamics which comprises of the demand side, supply-side and economy side drivers, market restraints, challenges and opportunities and trends which are prevailing in this market and impacting the growth of the market. Worldwide Reactive Arthritis Treatment Market highlights its existing absolute $ opportunity. Further, this market is likely to achieve considerable absolute $ opportunity by the year 2026 as compared to the value achieved in the year 2018.

The global Reactive Arthritis Treatment Market study comprises of risk analysis which covers market demand risk and market supply risk impacting the growth of this market. Further, the report covers a section on correlation and regression analysis in which the relationship between independent and dependent variables have been analyzed to have better clarity and understanding of the market. The global Reactive Arthritis Treatment Market includes a chapter on macro-economic indicators impacting the growth of this market.

Further, a separate section in the report highlights the geography scenario in this market which includes North America (further bifurcated into U.S. and Canada).

Based on the geographical analysis, the report covers the market scenario for the following regions around the world:

A series of illustrations such as graphs, tables, and charts are provided in the report to make the report easy to comprehend for the business clients.

The Final Report will cover the impact analysis of COVID-19 on this industry (Global and Regional Market).

Request for a Sample Copy (including TOC, Tables, and Figures) of Research Report:https://www.kennethresearch.com/sample-request-10082863

Scope for the Customization:

We are open for the customization of this report for our client.

Table of Content:

Key Answers Captured in Report?

The Final Report will cover the impact analysis of COVID-19 on this industry (Global and Regional Market).

Request for Complete Report:https://www.kennethresearch.com/sample-request-10082863

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations, and organizations with the aim of helping them to take prominent decisions. Our research library comprises more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both the macro level as well as micro-level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis of various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keeps a track of the international and domestic market for any economic changes impacting the products demand, growth, and opportunities for new and existing players.

New Research Reports Available @Kenneth Research:

School Administrative Software MarketSaaS-based ECM MarketSaaS-based Content Security MarketSaaS-based Business Intelligence MarketSaaS Security MarketRisk IT and Services in the BFSI Sector Market

The rest is here:
Reactive Arthritis Treatment Market Share, Top Companies, Impact of COVID-19 on Global Trends, Growth Opportunity And Forecast 2018-2026 - 3rd Watch...

Arthritis is a problem associated with joints, in which a person suffers from red, hot, swollen and functionally impaired joints. Rheumatoid arthritis is a type of arthritis that is caused due to loss of tissue lining. A new research report by Persistence Market Research focuses on the various treatment options for rheumatoid arthritis and presents a forecast for this market for next few years.

The report is titledRheumatoid Arthritis Treatment Market: Global Industry Analysis 2012 2016 and Forecast 2017 2025and reveals the findings of this exhaustive research program. According to the report insights, the globalrheumatoid arthritis marketheld a market value of over US$ 23,900 Mn in 2017, which is expected to reach a valuation in excess of US$ 37,800 Mn by the end of 2025, growing at a CAGR of 5.9%.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/22555

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/22555

Rheumatoid Arthritis Therapies Market: Snapshot

The growth of the rheumatoid arthritis market is driven by macro-economic factors like the increase in aging population of many countries, which subsequently increases the number of patients suffering from rheumatoid arthritis. The prevalence of this disease is also seen to be high in women; one in every 12 women develops rheumatoid arthritis during her lifetime.

There is also a rise in awareness about the disease in many developed regions. This has increased the rate of disease treatment rather than symptoms treatment. As people are more aware about rheumatoid arthritis they get more inclined towards treating the disease, thereby boosting the sales of drugs in the rheumatoid arthritis treatment market.

These factors are expected to mark the advent of a bunch of new products that will hit the market within the next eight years.

North Americas Dominance to be Overshadowed by APACs Faster Growth Rate

The North America rheumatoid arthritis market held the highest market value in the past and is also expected to continue leading the global market in future, with a market value of over US$ 16,000 Mn estimated by the end of 2025. However, Asia Pacific is an emerging leader in the competition and is expected to grow at the highest rate of 7.9% during the forecast period 2017-2025.

Middle East and Africa is also expected to show huge scope for development in the global market. Rheumatoid arthritis is one of the leading causes of disability in the Middle East and Africa. A study reveals that prevalence of the disease is reported to be at 0.3% in Egypt and 0.4% in Lesotho. Considering the poor yet fastest growing economy of Africa, generic players have massive scope for growth in the region.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/22555

Top Market Companies and Their Major Challenges

This research report comprises a detailed presentation of all the companies leading in the global market. These companies are considered to hold a higher customer base than any other companies in the industry. The drugs manufactured by these companies are widely used in the global market and there are several other products in the pipeline. Some of these companies mentioned in the report are Sanofi SA, Pfizer Inc., Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc. and Sobi Inc.

Continue reading here:
Rheumatoid Arthritis Treatment Market Is Projected To Grow US$ 30000 Mn By 2025 - WaterCloud News

Objective:To investigate metabolic syndrome (MetS), disease activity, and adipokine levels among patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), and undifferentiated arthritis (UA) at the time of diagnosis and after 1 year of follow-up.

Methods:Patients with inflammatory joint diseases participating in the Northern Savo 2010 population-based prospective epidemiological study were evaluated for components of MetS (by National Cholesterol Education Programs Adult Treatment Panel III) and clinical parameters of disease activity. The adipokines adiponectin, adipsin, resistin, and leptin were measured at baseline and after 1 year of treatment with disease-modifying antirheumatic drugs.

Results:Among 176 patients, MetS was detected in 42% of RA, 36% of SpA, and 51% of UA patients. Metabolic syndrome was associated with higher disease activity as measured by patient global assessment in RA and UA patients and increased pain in RA patients. Leptin levels were increased in patients with MetS, showing a linearly increasing trend with the number of components of MetS in SpA and UA, but not in RA. In RA patients, decrease in disease activity correlated with decrease in leptin levels. Resistin did not associate with MetS, but a decrease in resistin correlated with decrease in disease activity in RA and UA. In SpA, increased adiponectin level correlated with relief in disease activity, but not with MetS.

Conclusions:Metabolic syndrome was common in patients with newly diagnosed arthritides and associated with higher disease activity and increased leptin levels. Resistin responded to treatment of arthritis in RA and UA, leptin in RA, and adiponectin in SpA.

Continue reading here:
Metabolic Syndrome, Disease Activity, and Adipokines in Patients With Newly Diagnosed Inflammatory Joint Diseases - DocWire News

PITTSBURGH The coronavirus pandemic has forced charities or nonprofit groups to cancel or postpone an untold number of walks and runs that raise money for everything from Alzheimers to Parkinsons.

There is, however, room to evolve.

When the Arthritis Foundations Pittsburgh chapter scrubbed its annual Walk to Cure Arthritis Event scheduled for May 16, it gave the 242 registrants a certain freedom.

People could kind of do what they wanted at their own pace and at their convenience, said Linda Glace, development manager for the foundations western Pennsylvania and West Virginia chapter.

Such a move could potentially allow organizations to expand their footprint in the future because it would remove geographical barriers.

The nonprofit WORK amended its Run Across Haiti to Run Across May to incorporate just about anything, be it running 200 miles by May 31, doing 200 lunges or baking 200 cookies and using hashtags on social media to promote it in hopes of raising awareness. The American Cancer Societys first Lakes to Bay 5K is a virtual run is a relay that started around the Finger Lakes in New York on May 11 and will wrap up on the Chesapeake Bay in Maryland on May 31. Registered runners were encouraged to take a picture during their respective legs and share it on social media.

The Pittsburgh Marathons Run for A Reason program generates around $1 million annually for 35 various nonprofits, most of them locally based. Though organizers offered refunds when the race weekend scheduled for early May was canceled, about 1,100 who signed up to run for charity stuck it out and completed their prescribed distance on their own.

They still all got their medal and their shirt and their sunglasses, said Allison Corbett, senior vice president for P3R, which helps organize most major road races around the city, including the marathon and half-marathon. People are still excited to get the race swag that they earn. It all comes back to that sense of community.

A sense that will be tested in the coming months and perhaps years as charities and those that support them deal with a new normal. Charity runners by the tens of thousands flood courses across the country each year. They run for their parents. Their siblings. Their friends. Themselves. Exercising and raising money for a cause close to them scratches two itches at once.

Training can be a slog, but the events themselves can be glorious. Trying to keep that energy going when the adrenaline rush that comes with lining up alongside others united for a common purpose will be difficult if social distancing rules remain in place for a long time.

Nothing beats the in-person interaction, said WORK executive director Vivien Luk. Were keeping an eye out on when we can (Run Across Haiti) again and doing it louder than before.

Today's breaking news and more in your inbox

See the article here:
Charitable runs, walks learn to adapt to crowd limits - The Daily Times

After experiencing an ACL injury, a common sports injury involving ligaments in the knee, many athletes find they cant return to play with the same vigor as before their injury. But, a new study, published in The American Journal of Sports Medicine, finds human growth hormonetreatment after ACL reconstructive surgery may prevent the loss of muscle strength in the knee.

While modern surgical techniques can reconstruct ACLs in a minimally invasive way, the associated muscle atrophy can be a greater challenge to overcome, says Asheesh Bedi, M.D., senior author of the study, chief of sports medicine and shoulder surgery at Michigan Medicine and director of the Michigan Center for Human Athletic Medicine and Performance (MCHAMP).

LISTEN UP: Add the new Michigan Medicine News Break to your Alexa-enabled device, or subscribe to our daily updates on iTunes,Google Play andStitcher.

Residual atrophy can slow or limit the safe return to the prior level of competition, and contribute to risk of re-injury and even arthritis.

HGH, a hormone within the body, helps cells and tissues grow and regenerate. HGH supplements are banned by the World Anti-Doping Agency, and in collegiate and professional sports.

When you hear of athletes taking HGH drugs when they are healthy, its considered doping because they are essentially trying to overproduce the hormone and bulk their muscles and tissues as a competitive advantage, says Christopher Mendias, Ph.D., ATC, the lead author of the study, an adjunct associate professor of orthopaedic surgery at Michigan Medicine and an associate scientist in the Arthritis and Tissue Degeneration Program at the Hospital for Special Surgery.

Bedi and Mendias hypothesized that administering HGH supplements to injured athletes may activate HGH within the body to target the ACL tear and prevent the knee muscles from losing strength.

Even after rehabilitation, many patients have muscles that are 30 to 40% weaker when they return to sports compared to their pre-surgery strength, Mendias says.

The researchers examined 19 male athletes, ages 18 to 35, with ACL tears who were scheduled for ACL reconstruction surgery at Michigan Medicine. The study participants were randomly assigned to self-inject HGH or a placebo solution into their lower abdominal muscles twice daily over a six-week period, beginning one week prior to surgery. The research team excluded collegiate, professional or elite athletes from the study because of the substance ban, as well as patients with diabetes, as developing type 2 diabetes is a side effect of HGH supplements.

Prescription HGH is only available for treating growth hormone deficiency syndromes and cant be used off-label without approval from the U.S. Food and Drug Administration. By obtaining an investigational new drug exemption from the FDA, the research team was able to administer the drug to study enrollees.

Other Michigan Medicine faculty and graduate students contributing to the study include Tariq Awan, D.O., an assistant professor of orthopaedic surgery, Ariel Barkan, M.D., a professor of internal medicine, James Carpenter, M.D., a professor and former chair of orthopaedic surgery, Joel Gagnier, N.D., Ph.D., an associate professor of orthopaedic surgery, Jonathan Gumucio, Ph.D., a graduate student in molecular and integrative physiology, and Jon Jacobson, M.D., a professor of radiology. The multidisciplinary team assured a rigorous scientific approach and the highest level of safety to the study.

The research team found the HGH injections did appear to have an effect after measuring knee muscle strength and volume, patient-reported outcomes, such as pain and symptoms, and analyzing biomarkers in blood samples from the injured athletes versus individuals without an ACL tear.

While HGH did not appear to affect muscle volume or our patient-reported outcome scores, we found a 29% higher knee extension strength in our patients that had performed the HGH injections compared to those in the placebo group, Bedi says.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

Examining the blood analyses revealed other signs of muscle and cartilage change. Patients who performed the HGH treatments had a 2.1-fold increase in circulating insulin-like growth factor 1 (IGF1), a protein similar to insulin that plays an important role in muscle growth. In addition, their blood samples indicated a 36% lower level of matrix metalloproteinase3 (MMP3), an enzyme that breaks down proteins during growth processes in the body. MMP3 was an indirect biomarker of cartilage wear down in the study.

We observed a consistent reduction in MMP3 in the HGH group from the first through the 12th post-operative weeks, Mendias says. This finding suggests a potential protective effect of HGH after ACL reconstruction and that we should look more closely at its potential for cartilage healing in further studies.

Bedi and Mendias hope the results of this study allow for revisiting reevaluation of the World Anti-Doping Agency and sports agencies ban on HGH.

Perhaps athletes could petition for a Therapeutic Use Exception, which allows a banned substance for a medically-appropriate reason, to prevent loss of muscle strength after ACL reconstruction, Mendias says. Treatment occurs during a time when athletes are not playing due to their injuries. The goal is to prevent muscle weakness, not make athletes stronger than they were before their injuries. Any small performance-enhancing effects of human growth hormone seem to wear off quickly after stopping the medication, and does not offer a competitive advantage.

The research team notes that further studies into HGH are needed.

We hope to build upon this research with future studies that include larger cohorts of athletes with broader demographics, Bedi says.

Mendias adds, Further studies would also allow us to petition the FDA to approve the addition of orthopedic injuries as an on-label indication for the drug.

The study was supported by funding provided by the Mark Cuban Foundation and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, a branch of the National Institutes of Health.

Paper cited: The Use of Recombinant Human Growth Hormone to Protect Against Muscle Weakness in Patients Undergoing Anterior Cruciate Ligament Reconstruction, The American Journal of Sports Medicine. DOI: 10.1177/0363546520920591.

The rest is here:
Human Growth Hormone Treatment After ACL Injury May Prevent Loss of Muscle Strength - Michigan Medicine

Rheumatoid Arthritis Diagnostic Device Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The report provides both quantitative and qualitative information of global Rheumatoid Arthritis Diagnostic Device market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Rheumatoid Arthritis Diagnostic Device is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Rheumatoid Arthritis Diagnostic Device market was valued at USD _ million/billion.

This research report based on Rheumatoid Arthritis Diagnostic Device market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Rheumatoid Arthritis Diagnostic Device market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Rheumatoid Arthritis Diagnostic Device industry.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2602783&source=atm

Rheumatoid Arthritis Diagnostic Device Market Overview:

The Research projects that the Rheumatoid Arthritis Diagnostic Device market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

The report on the Rheumatoid Arthritis Diagnostic Device market provides a birds eye view of the current proceeding within the Rheumatoid Arthritis Diagnostic Device market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Rheumatoid Arthritis Diagnostic Device market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Rheumatoid Arthritis Diagnostic Device market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Leading manufacturers of Rheumatoid Arthritis Diagnostic Device Market:

The key players covered in this studyAbbott LaboratoriesDanaher Corp.F. Hoffmann-La Roche Ltd.Siemens Healthineers AGThermo Fisher Scientific Inc.

Market segment by Type, the product can be split intoAnalyzersConsumablesMarket segment by Application, split intoHospitalResearch instituteClinicOther

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Rheumatoid Arthritis Diagnostic Device status, future forecast, growth opportunity, key market and key players.To present the Rheumatoid Arthritis Diagnostic Device development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Rheumatoid Arthritis Diagnostic Device are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2602783&source=atm

Some important highlights from the report include:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2602783&licType=S&source=atm

The Questions Answered by Rheumatoid Arthritis Diagnostic Device Market Report:

And Many More.

Read the original post:
Assessing the Fallout From the Coronavirus Pandemic Rheumatoid Arthritis Diagnostic Device Market : Drivers, Restraints, Opportunities, and Threats...

Charity digital leaders have responded with innovation and dynamism in the wake of COVID-19 lockdown restrictions. Reinvigorating digital solutions for service delivery and supporter outreach, tech for good efforts have benefited from renewed interest.

Taking a closer look at tech for good efforts in the healthcare sector, we review these new developments and what might be taken forward in a broader context.

The governments call for 250,000 volunteers across the community to support coronavirus sufferers was met with a thunderous response. Tech for good solutions quickly emerged to help fight the crisis and manage over 750,000 respondents.

Prior to the crisis, GoodSam, an international charity, was already operating mobile, app-based alert systems and dispatching services. When the government called for volunteers to help community members who are self-isolating, GoodSam quickly pivoted its digital service into action. The app now allows volunteers to not only do good for the NHS but also within the local community. Once downloaded, local citizens in need can contact others to assist in grocery shopping, transporting medicines, or simply just for company. For charities operating health, fire, and ambulance services, the app can also access the callers mobile phone camera in an emergency situation, improving service delivery ahead of the arrival of help.

Likely to trend onwards, GoodSams quick, innovative pivot to crowdsourcing could potentially be a model for other charities to emulate.

The pandemic has brought into focus just how important tech for good is at supporting not only charities but their beneficiaries. Tech for good efforts by charities have helped bring patients and doctors closer together, and we expect, that post-pandemic, these relationships will continue to align.

Aiming to help young arthritis sufferers, Versus Arthritis launched a mobile phone app to support young people between the ages of 13-25. The charitys app helps users keep track of their symptoms like an electronic diary. For healthcare professionals unable to attend patients who are self-isolating, tracking symptoms is important to prescribing the right care.

It has huge potential to enhance communication between young people and health professionals, allowing us to better understand the impact arthritis is having on the young persons life and then to treat them more effectively. Since the COVID-19 outbreak, the app has even greater potential. It can be difficult to assess young people on the phone so using their app summaries as a prompt or by sharing on email beforehand, it will really help these phone consultations, said Dr Janet McDonagh, a paediatric and adolescent rheumatologist at Royal Manchester Childrens Hospital.

New tech for good partnerships have formed between healthcare workers, charities, and private tech developers. Looking ahead, we can expect to see more digital collaborations between charities and other service providers.

During the past few months, the Hospify mobile phone app has been expanding its service base to NHS charities, trusts, and healthcare professionals. Tackling the problem of confidentiality and security, Hospify developed a secure-message aggregator for messages coming in from sources like WhatsApp, Signal, Telegram and Messenger, which are often not company or charity approved. By securing messages from other sources, the app allows doctors, nurses, patients, pharmacists, dentists, and patients to connect in online groups and share information (including pictures) without jeopardising confidentiality. The app is now servicing over 150 hospitals and has been vetted by the NHS as one of its approved apps.

Coronavirus took the world by surprise, and researchers are still scrambling to find a cure. Funded by charities and partners NHS Digital, Open Data Institute Leeds and Beautiful Information, the #OpenDataSavesLives hackathon threw open the doors for anyone and everyone to participate in making sense of big data. Over 50 participants, including the British Red Cross, shared standardised, integrated information to get a broader picture of cities.

Paul Connell, founder of Open Data Institute Leeds said: #OpenDataSavesLives can bring people together to respond to the situation we are all facing. We want to encourage and empower people to work in the open, talk about your work, ask for help, share your success on our open doc. We can then link up the incredible work being done, remove barriers and speed up the response.

Looking ahead thematically, the sharing of big data has the potential to help charities unlock information barriers to solve big issues, including poverty, homelessness, and many others. By improving transparency and better information, tech for good efforts can address and help charities deliver their missions.

See original here:
Tech to the rescue!: What COVID-19 means to the future of tech for good - Charity Digital News

Arthritis has name recognition, even among people who are not suffering from it. But despite that recognition, arthritis is not as well understood as one might think.

According to the Arthritis Foundation, arthritis is not a single disease, but rather an informal way of referring to joint pain or joint disease. In fact, the term arthritis is so wide-ranging that it actually refers to more than 100 types of conditions.

Despite that complexity, arthritis often produces four important warning signs, regardless of which type of arthritis a person may have.

1. Pain

The Arthritis Foundation notes that arthritis-related pain may be constant or intermittent. One common misconception about arthritis pain is that it only occurs during or shortly after a body is at rest. However, arthritis-related pain can occur while the body is at rest and is not always triggered by an activity that incorporates a part of the body affected by arthritis. In addition, pain from arthritis can be isolated to one area of the body or affect various parts of the body.

2. Swelling

Skin over the joints affected by arthritis may become red and swollen. This skin also may feel warm to the touch. The Arthritis Foundation advises anyone who experiences this swelling for three days or longer or more than three times per month to contact a physician.

3. Stiffness

This warning sign is, along with pain, the one that is most often associated with arthritis, even by people who dont suffer from the condition. Stiffness when waking up in the morning or after long periods of being sedentary, such as sitting at a desk during the workday or taking a long car ride, can be symptomatic of arthritis, especially if the stiffness lasts an hour or longer.

4. Difficulty moving a joint

The Arthritis Foundation notes that people should not experience difficulty moving, such as when getting out of bed. People who experience such difficulty may have arthritis.

People who recognize any of these warning signs should report them to their physicians immediately. Be as specific as possible when describing these symptoms, as specificity can help physicians design the most effective course of treatment.

Read more:
Common warning signs of arthritis | Health | willistonherald.com - Williston Daily Herald

Doctors say that what you eat may help with some of the inflammation we see with arthritis

by: Len Rome

(WYTV) Millions of Americans suffer from arthritismand sometimes it really hurts.

The most common form is degenerative arthritis, also known as osteoarthritis, followed by rheumatoid arthritis.

Doctors say that what you eat may help with some of the inflammation we see with arthritis.

John Davis III, M.D. Rheumatology from The Mayo Clinic says avoiding foods such as potato chips and pizza could help ease your arthritis pain.

Some foods can increase inflammation levels and contribute to symptoms of arthritis, especially really fatty foods simple sugars or carbohydrates, lots of salt or salty food.

The symptoms may include swollen and achy joints, discomfort and pain.

While medication may help joint pain, exercise, maintaining a healthy weight and paying attention to the food you eat play important roles.

Add more fruits and vegetables, healthy fats such as olive oil and nuts, whole grains and fish.

These foods can help reduce inflammation and ease pain.

Originally posted here:
Len Romes Local Health: The impact of foods on arthritis - WYTV

In a desperate attempt to avoid the coronavirus or to make existing infections worse, arthritic patients are looking for alternative treatments for their ailment. Some even consider bizarre ones, such as the industrial lubricant, WD-40, in place of ibuprofen.

Many now fear the effects of the over-the-counter drug after previous speculations by scientists that it could make coronavirus symptoms worse. Ibuprofen has long been the drug of choice of arthritis, which many rely on to be able to walk without going through excruciating pain.

Sid Dajani, a pharmacist in Hampshire and former treasurer of the Royal Pharmaceutical Society, said that mixed messages about ibuprofen have caused people to avoid the drug altogether. According to Daily Mail, some have resorted to alternatives that seem rather odd, such as snake oils, aloe vera, and even the industrial degreaser, WD-40.

He adds that despite the NHS' latest advisory stating the drug is safe to take, sales remain to be at around a third of their normal levels.

Read Also: COVID-19: Arthritis Drug Saves 72-year-old Critically Ill Patient with Grim Condition

Worries about the drug started on March 14, when Olivier Veran, the French health minister said ibuprofen could aggravate coronavirus infections.

His comments are thought to be partly planted by remarks coming from an infectious diseases doctor. He mentioned about four young COVID-19 patients with no underlying health conditions developing severe symptoms after taking ibuprofen. A letter that had been published in the journal Lancet Respiratory Medicine three days earlier might have also caused him to believe this.

On March 16, the authors released a clarification statement saying they had merely been proposing a 'suspicion'. The following day, however, the NHS advised people with COVID-19 symptoms to avoid taking ibuprofen and instead use paracetamol.

Advice shifted again in April after the Commission on Human Medicines concluded that there is insufficient evidence that ibuprofen makes people more likely to catch COVID-19 or worsen its symptoms.

It has been reported that some were even using WD-40 on their joints, thinking that it will ease stiff joints the same way it loosens stubborn locks. Others tried using aloe vera while some went searching online for other adventurous remedies such as snake oil lotions and potions.

Dajani described how upsetting it is to see patients in pain turn to unproven or dangerous remedies when ibuprofen could help them. He describes the event as a tragedy that should not be happening.

Dr. Taher Mahmud, a consultant rheumatologist from the London Osteoporosis Clinic, said that it was 'very sad and concerning' that patients are utilizing faulty home remedies such as WD-40.

Experts believe that there is a distinct concern when it comes to pre-print and early drafts of medical and scientific papers that have not been peer-reviewed. These kinds of studies are particularly being given undue weight during the pandemic, being an easy target for criticisms and early speculations.

Also Read: Claims Ibuprofen Worsen COVID-19 are Baseless, According to EU

Original post:
Arthritis Patients Resort to Using Industrial Lubricant Over Fears Ibuprofen Might Worsen Coronavirus - Science Times